EA201400178A1 - BREAST CANCER TREATMENT - Google Patents

BREAST CANCER TREATMENT

Info

Publication number
EA201400178A1
EA201400178A1 EA201400178A EA201400178A EA201400178A1 EA 201400178 A1 EA201400178 A1 EA 201400178A1 EA 201400178 A EA201400178 A EA 201400178A EA 201400178 A EA201400178 A EA 201400178A EA 201400178 A1 EA201400178 A1 EA 201400178A1
Authority
EA
Eurasian Patent Office
Prior art keywords
breast cancer
cancer treatment
treatment
compounds used
application describes
Prior art date
Application number
EA201400178A
Other languages
Russian (ru)
Other versions
EA028452B1 (en
Inventor
Эндрю А. Проттер
Дженнифер Ричер
Дон Кокрейн
Original Assignee
Медивейшн Простейт Терапьютикс, Инк.
Те Риджентс Оф Те Юниверсити Оф Колорадо, Э Боди Корпорейт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201400178(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Медивейшн Простейт Терапьютикс, Инк., Те Риджентс Оф Те Юниверсити Оф Колорадо, Э Боди Корпорейт filed Critical Медивейшн Простейт Терапьютикс, Инк.
Publication of EA201400178A1 publication Critical patent/EA201400178A1/en
Publication of EA028452B1 publication Critical patent/EA028452B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Заявка описывает соединения, применяемые при лечении рака молочной железы.The application describes compounds used in the treatment of breast cancer.

EA201400178A 2011-07-29 2012-07-27 Treatment of breast cancer EA028452B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (2)

Publication Number Publication Date
EA201400178A1 true EA201400178A1 (en) 2014-11-28
EA028452B1 EA028452B1 (en) 2017-11-30

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400178A EA028452B1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Country Status (18)

Country Link
US (4) US9517229B2 (en)
EP (4) EP3610731A1 (en)
JP (2) JP6158180B2 (en)
KR (1) KR101923250B1 (en)
CN (1) CN103997894B (en)
BR (1) BR112014002200A2 (en)
CA (1) CA2843417C (en)
CY (1) CY1121038T1 (en)
DK (1) DK2739153T3 (en)
EA (1) EA028452B1 (en)
ES (1) ES2696074T3 (en)
HK (2) HK1198867A1 (en)
HU (1) HUE040524T2 (en)
MX (1) MX359664B (en)
PL (1) PL2739153T3 (en)
PT (1) PT2739153T (en)
SI (1) SI2739153T1 (en)
WO (1) WO2013066440A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6158180B2 (en) * 2011-07-29 2017-07-05 メディベイション プロステイト セラピューティクス， インコーポレイテッド Breast cancer treatment
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
ES2836424T3 (en) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrogens to treat castration-resistant and non-metastatic prostate cancer
JOP20200097A1 (en) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
CA2908957C (en) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
JP6945587B2 (en) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー Methods of Inhibiting TIE2 Kinase Useful for Cancer Treatment
WO2015069266A1 (en) * 2013-11-07 2015-05-14 Flynn Daniel L Methods for inhibiting tie2 kinase useful in the treatment of cancer
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
BR112017012142A2 (en) 2014-12-12 2018-01-02 Medivation Prostate Therapeutics Inc method for predicting response to therapeutic agents for breast cancer and method for treating breast cancer
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
EP3265063A4 (en) 2015-03-03 2018-11-07 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN104857517B (en) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 A kind of miscellaneous Shandong amine soft capsule of grace and preparation method thereof
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
BR112019027402A2 (en) 2017-06-22 2020-07-07 Celgene Corporation treatment of hepatocellular carcinoma characterized by infection with the hepatitis b virus
EP3697398A1 (en) 2017-10-16 2020-08-26 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (en) * 2017-12-19 2018-05-04 刘秀云 Thiocarbamoyl imidazole diones androgen receptor antagonists and application thereof
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AU2019387367A1 (en) * 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
MX2022001863A (en) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors.
TW202122082A (en) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 Methods of treating gastrointestinal stromal tumors
LT4084778T (en) 2019-12-30 2024-01-25 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
IL293864A (en) 2019-12-30 2022-08-01 Deciphera Pharmaceuticals Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (en) 1983-08-30 1985-04-24 Oreal COSMETIC OR PHARMACEUTICAL COMPOSITION IN AQUEOUS OR ANHYDROUS FORM WHOSE FATTY PHASE CONTAINS OLIGOMER POLYETHER AND NEW OLIGOMER POLYETHERS
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
ES2535179T3 (en) 2005-05-13 2015-05-06 The Regents Of The University Of California Diarylhydantoin compound as androgen receptor antagonists for cancer treatment
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
WO2007061876A2 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
DK2368550T3 (en) * 2006-03-27 2013-09-30 Univ California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
EP2439196A1 (en) 2006-03-29 2012-04-11 The Regents of The University of California Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder
UY31432A1 (en) 2007-10-26 2009-05-29 DIARILHIDANTOINE COMPOUNDS
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
US20110130296A1 (en) * 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
DK2297359T3 (en) 2008-05-30 2014-02-24 Univ Utah Res Found Gene expression profiles to predict the outcome of breast cancer
RU2548918C2 (en) 2009-02-24 2015-04-20 Медивэйшн Простейт Терапьютикс, Инк. Specific diarylhydantoin and diarylthiodiaryl compounds
WO2010118354A1 (en) 2009-04-09 2010-10-14 Medivation Prostate Therapeutics, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof
WO2011022316A1 (en) * 2009-08-20 2011-02-24 The Regents Of The University Of Colorado, A Body Corporate Mirnas dysregulated in triple-negative breast cancer
EP2485804A4 (en) * 2009-10-07 2015-07-29 Medivation Technologies Inc Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
JP5971769B2 (en) 2011-03-15 2016-08-17 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル Methods of treating breast cancer using anthracycline therapy
JP6158180B2 (en) * 2011-07-29 2017-07-05 メディベイション プロステイト セラピューティクス， インコーポレイテッド Breast cancer treatment
EP2785873A4 (en) 2011-11-30 2015-11-11 Univ North Carolina Methods of treating breast cancer with taxane therapy
EP2888594B1 (en) 2012-08-23 2018-08-15 The Regents of the University of Colorado, a body corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US20140154681A1 (en) 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
BR112017012142A2 (en) 2014-12-12 2018-01-02 Medivation Prostate Therapeutics Inc method for predicting response to therapeutic agents for breast cancer and method for treating breast cancer

Also Published As

Publication number Publication date
KR101923250B1 (en) 2018-11-28
EA028452B1 (en) 2017-11-30
DK2739153T3 (en) 2018-12-03
EP3430907A1 (en) 2019-01-23
MX2014001218A (en) 2014-08-22
US10111861B2 (en) 2018-10-30
BR112014002200A2 (en) 2017-03-07
CN103997894B (en) 2016-08-24
WO2013066440A1 (en) 2013-05-10
KR20140107174A (en) 2014-09-04
US9517229B2 (en) 2016-12-13
CA2843417C (en) 2018-08-21
WO2013066440A9 (en) 2013-07-18
CY1121038T1 (en) 2019-12-11
EP3791724A1 (en) 2021-03-17
EP2739153B1 (en) 2018-08-22
SI2739153T1 (en) 2018-12-31
EP2739153A1 (en) 2014-06-11
EP2739153A4 (en) 2015-03-11
PL2739153T3 (en) 2019-04-30
US20210069154A1 (en) 2021-03-11
HK1198867A1 (en) 2015-06-19
CN103997894A (en) 2014-08-20
PT2739153T (en) 2018-11-28
ES2696074T3 (en) 2019-01-14
US20190262315A1 (en) 2019-08-29
JP2014524934A (en) 2014-09-25
CA2843417A1 (en) 2013-05-10
HUE040524T2 (en) 2019-03-28
US20140296312A1 (en) 2014-10-02
HK1201413A1 (en) 2015-09-04
EP3610731A1 (en) 2020-02-19
MX359664B (en) 2018-10-05
JP2017141269A (en) 2017-08-17
US20170087132A1 (en) 2017-03-30
JP6158180B2 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
EA201400178A1 (en) BREAST CANCER TREATMENT
EA201171367A1 (en) VINYLINDASOLYL COMPOUNDS
EA201590987A1 (en) CONNECTIONS AND METHODS OF THEIR APPLICATION
EA201590997A1 (en) CONNECTIONS AND METHODS OF THEIR APPLICATION
CL2012003385A1 (en) Incontinence treatment.
TR201813877T4 (en) COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY.
EA201300810A1 (en) ANTI-TRACT THERAPY USING DOUBLE INHIBITORS KINAZ AURORA / MEK
EA201270619A1 (en) USE OF BETANEHOL FOR THE TREATMENT OF XEROSTOMY
BR112014007603A2 (en) cancer treatment methods
CY1123716T1 (en) ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC, EUNAUCH-RESISTANT PROSTATE CANCER
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
EA201491447A1 (en) ENDINES, THEIR CONJUGATES AND METHODS FOR THEIR RECEPTION AND APPLICATION
UY34817A (en) TIENOPIRIMIDINS
BR112013024211A2 (en) solid tumor treatment
EA201490559A1 (en) COMPOSITION FOR THE TREATMENT OF Fistula
UY34582A (en) ANTI-CXCR3 ANTIBODIES
BR112014012880A2 (en) immunogenic cancer treatment
MX359769B (en) Methods of decellularizing bone.
EA201591024A1 (en) DIMER CONNECTIONS
SMT201600235B (en) PREDICTORS FOR CANCER TREATMENT
EA201590503A1 (en) ALPHA-1-Microglobulin for use in the treatment of diseases associated with mitochondria
EA201591709A1 (en) 5-BROMED INDIRUBINES
UY34677A (en) IMIDAZOPIRIDAZINAS REPLACED
UY34543A (en) DERIVATIVES OF SULFONYLAMINOPIRROLIDINONE, ITS PREPARATION AND THERAPEUTIC APPLICATION.
EA201590615A1 (en) STIMULATING LACTATION COMPOSITIONS BASED ON PHOSPHATIDIDILSERIN

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM